

THE LANCET

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for *Helicobacter pylori* infection in seven Latin American sites: a randomised trial. *Lancet* 2011; published online July 20. DOI:10.1016/S0140-6736(11)60825-8.

Table 5 (Supplement): Summary of *H. pylori* eradication by treatment arm and study centre for adherent population.

Treatment Regimen	N	Eradicated		Difference from Standard	Adjusted 95% CI	P-value for Interaction*
		N	Percent			
Study Site						0.21
Santiago, Chile						
Standard	57	53	93.0%			
Concomitant	56	44	78.6%	14.4%	0.0%, 28.9%	
Sequential	59	52	88.1%	4.8%	-9.0%, 18.7%	
Túquerres, Colombia						
Standard	71	58	81.7%			
Concomitant	72	58	80.6%	1.1%	-13.5%, 15.8%	
Sequential	67	53	79.1%	2.6%	-14.0%, 19.2%	
Guanacaste, Costa Rica						
Standard	67	59	88.1%			
Concomitant	65	50	76.9%	11.1%	-3.6%, 25.8%	
Sequential	64	59	92.2%	-4.1%	-17.3%, 9.0%	
Copán, Honduras						
Standard	66	63	95.5%			
Concomitant	69	60	87.0%	8.5%	-2.3% , 19.3%	
Sequential	70	58	82.9%	12.6%	-0.5% , 25.7%	
Tapachula, México						
Standard	59	51	86.4%			
Concomitant	65	50	76.9%	9.5%	-5.9%, 24.9%	
Sequential	65	47	72.3%	14.1%	-3.4%, 31.7%	
Ciudad Obregón, México						
Standard	58	51	87.9%			
Concomitant	63	45	71.4%	16.5%	0.5%, 32.5%	
Sequential	59	45	76.3%	11.7%	-5.7%, 29.1%	
León, Nicaragua						
Standard	56	43	76.8%			
Concomitant	52	41	78.8%	-2.1%	-20.0%, 15.9%	
Sequential	54	41	75.9%	0.9%	-18.2%, 19.9%	

*P-value for Chi-squared drop-in-deviance test for significance of interaction with treatment regimen in a logistic regression model controlling for main effects of treatment and baseline covariate